# **Patient Information Document**

NO136-PI1 — 2024-09

FΝ



# **TRACHEOBRONXANE** DUMON DUMON

Tracheo-bronchial Silicone Stent





# **NOVATECH SA**

Société anonyme au capital de 160.000€ 398 941 260 RCS Marseille TVA CEE FR59398941260 Certifiée selon EN ISO 13485

Z.I.Athélia III - 1058, Voie Antiope F-13705 La Ciotat CEDEX France Tel +33 (0) 442 98 15 60 Fax +33 (0) 442 98 15 63 info@novatech.fr www.novatech.fr

 $72057594509779083 - 16.09.2024\ 15:53$ 



#### 1 Dear Patient,

You have been given an implant of the type TRACHEOBRONXANE DUMON. For your own safety, please read this Patient Information Document carefully and keep it somewhere safe. If you have any questions about your implant, please contact the physician who treats you.

#### 2 About this Document

#### 2.1 Symbols Glossary

Symbol	Description
MR	MR safe
REF	Catalog number
LOT	Batch code
UDI	Unique Device Identification (UDI)
***	Manufacturer
<b>†</b> ?	Patient name
[31]	Date of implantation
Ų,	Name of the implanting healthcare institution / provider
<b>†i</b>	Patient information website

Table 1: Symbols Glossary

## 2.2 Safety Information Marking

# **MARNING**

Non-compliance may result in serious injuries, serious deterioration of your general condition or your death.

# 2.3 Additional Information

Download link for the Patient Information Document:1)	www.novatech.fr/pi/no136pi
This patient information is based on the following instruc-	NO136-1 (2024-09)
tions for use:	

<sup>1)</sup> Updated on an ongoing basis.

The catalog number and batch code for your implant can be found on your implant card.

#### 3 What you need to pay attention to

- 1. Always carry your implant card with you. Show your implant card and this Patient Information Document to your treating physician before undergoing diagnostic or therapeutic procedures.
- 2. To prevent any encrustation, perform regular damp inhalations with saline.
- 3. Contact your doctor if you experience one or more of the following symptoms: Foreign body sensation, halitosis (bad breath), bleeding
- 4. Stick to the appointments you make with your treating physician for follow-up examinations and observe their instructions for any necessary follow-up measures.

ATTENTION: Your TRACHEOBRONXANE DUMON must be monitored regularly by your attending physician. Be sure to keep your appointments for these follow-up examinations and follow your physician's advice on the necessary aftercare measures. This is especially true when the intended lifetime of your TRACHEOBRONXANE DUMON has been reached ([ > Expected Lifetime, page 3]).

## 4 Product Description

#### 4.1 General

• Tracheo-bronchial stent made of silicone

- Transparent or radiopaque (according to specification)
- 2, 3 or 4 rows of studs made of transparent or radiopaque silicone (depending on specification)

For specifications please refer to the implant card.

#### 4.2 Materials with Potential Patient Contact

Product (part)	Material	Contact person	Type of contact
TRACHEOBRONXANE DUMON (clear)	100% implant-grade silicone	Patient	With every use
TRACHEOBRONXANE DUMON (radiopaque)	100% blend of implant-grade silicone and barium sulphate		With every use

#### 5 Intended Use

# 5.1 Intended Purpose

The product is intended for use in the trachea and /or bronchus to keep the airway open.

The product is for long-term use.

#### 5.2 Patient Target Group

The product is suitable for use in the following patient groups:

- Infants and young children
- · Children and youth
- Adults
- · Patients of all genders

#### 5.3 Expected Lifetime

Expected lifetime of the product: 12 months

Unless an earlier replacement is needed, it is recommended to replace the product after 12 months as a precautionary measure.

## 6 Possible Complications and Side Effects

- Perforations
- · Stent migration
- Foreign body sensation
- Bleeding
- Ingrowth of / overgrowth with tissue
- Secretion obstruction
- · Formation of granulation tissue
- Ulceration of the tracheal or bronchial wall
- · Restenosis due to progressive tumor growth
- Infection
- Halitosis
- Coughing

## 7 Combining with Other Procedures

# **WARNING**

• Laser therapy, argon plasma coagulation, high-frequency surgery, and other procedures, the effect of which is due to heat: Do not use those methods directly on the product.

Otherwise, injury to the tissue and product damage are possible.

Any method for reducing tissue, such as chemotherapy or radiation therapy, can lead to stent migration.

The product is MRI safe.

#### 8 Other Residual Risks

Beyond the listed safety instructions, possible complications and side effects, no further significant residual risks are known.

# 9 Follow-up measures after removal of the product

The follow-up measures after removal of the product will depend on your underlying disease as well as your general health and shall be at the discretion of your treating physician.